157 related articles for article (PubMed ID: 28114175)
1. RISK FACTORS AND CLINICAL SIGNIFICANCE OF PRECHOROIDAL CLEFT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Kim JM; Kang SW; Son DY; Bae K
Retina; 2017 Nov; 37(11):2047-2055. PubMed ID: 28114175
[TBL] [Abstract][Full Text] [Related]
2. LONG-TERM COURSE AND VISUAL OUTCOMES OF PRECHOROIDAL CLEFT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
Kim JH; Kim JW; Kim CG; Lee DW
Retina; 2021 Dec; 41(12):2436-2445. PubMed ID: 34173365
[TBL] [Abstract][Full Text] [Related]
3. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration.
Berg K; Roald AB; Navaratnam J; Bragadóttir R
Acta Ophthalmol; 2017 Dec; 95(8):796-802. PubMed ID: 28926190
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
[TBL] [Abstract][Full Text] [Related]
5. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
[TBL] [Abstract][Full Text] [Related]
6. Prechoroidal cleft thickness correlates with disease activity in neovascular age-related macular degeneration.
Cozzi M; Monteduro D; Parrulli S; Ristoldo F; Corvi F; Zicarelli F; Staurenghi G; Invernizzi A
Graefes Arch Clin Exp Ophthalmol; 2022 Mar; 260(3):781-789. PubMed ID: 34491426
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of age-related macular degeneration with poor response to three loading doses of anti-vascular endothelial growth factor.
Sariyeva Ismayilov A; Duru Y; Çağlar T; Erseven C; Ulusoy MO
Int Ophthalmol; 2024 Jun; 44(1):264. PubMed ID: 38913217
[TBL] [Abstract][Full Text] [Related]
8. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
[TBL] [Abstract][Full Text] [Related]
9. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB
Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850
[TBL] [Abstract][Full Text] [Related]
10. RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Westborg I; Albrecht S; Rosso A
Retina; 2017 Nov; 37(11):2035-2046. PubMed ID: 28141748
[TBL] [Abstract][Full Text] [Related]
11. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
[TBL] [Abstract][Full Text] [Related]
13. The Evolution of Fibrosis and Atrophy and Their Relationship with Visual Outcomes in Asian Persons with Neovascular Age-Related Macular Degeneration.
Cheung CMG; Grewal DS; Teo KYC; Gan A; Mohla A; Chakravarthy U; Wong TY; Jaffe GJ
Ophthalmol Retina; 2019 Dec; 3(12):1045-1055. PubMed ID: 31444144
[TBL] [Abstract][Full Text] [Related]
14. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
Chang W; Garg SJ; Maturi R; Hsu J; Sivalingam A; Gupta SA; Regillo CD; Ho AC
Am J Ophthalmol; 2014 Jun; 157(6):1250-7. PubMed ID: 24531021
[TBL] [Abstract][Full Text] [Related]
15. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration.
Cho HJ; Koh KM; Kim JH; Kim HS; Han JI; Lew YJ; Lee TG; Kim JW
Retina; 2015 Feb; 35(2):205-12. PubMed ID: 25105310
[TBL] [Abstract][Full Text] [Related]
18. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
19. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
Lee H; Ji B; Chung H; Kim HC
Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
[TBL] [Abstract][Full Text] [Related]
20. Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents.
Enders P; Sitnilska V; Altay L; Fauser S
Ophthalmologica; 2018; 239(1):45-51. PubMed ID: 28950272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
